IRON · 2 developments mapped · last assessed 2026-09-01
Market Ontology has mapped 2 macro, policy, and market developments to Imara Inc. since 2026-09-01. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Last close
Unavailable
No published quote
Market cap
Unavailable
Equity value
Diluted shares
Unavailable
Latest reported
Sector
Unavailable
Listing
Unavailable
Filings
Unavailable
No published filing
Valuation
No validated run has been published for IRON yet, so no modelled value is shown. The IRON valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run IRON on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
A validated filed-statement snapshot has not been published for IRON. Missing data is not estimated or replaced with scenario assumptions.
Current case
Open question
Disc Medicine to Present Phase 2 Hematology Data at SOHO 2026
Indirect competitive landscape shift in hematologic disorders, particularly myelofibrosis, if DISC-0974 data is compelling.
· Moves competitive intensity in myelofibrosis market, market share potential for competing therapies
What changed, by assumption
Competitive intensity in myelofibrosis market
2026-09-01Disc Medicine to Present Phase 2 Hematology Data at SOHO 2026
Market share for competing therapies
2026-09-01Disc Medicine to Present Phase 2 RESTORE-PV and RALLY-MF Trial Data at SOHO